StockNews.com Begins Coverage on Aeterna Zentaris (NASDAQ:AEZS)

StockNews.com assumed coverage on shares of Aeterna Zentaris (NASDAQ:AEZS) (TSE:AEZ) in a research note issued to investors on Friday. The brokerage issued a sell rating on the biopharmaceutical company’s stock.

Aeterna Zentaris Stock Performance

Shares of NASDAQ AEZS opened at $3.36 on Friday. Aeterna Zentaris has a 1 year low of $3.96 and a 1 year high of $12.00. The firm has a market cap of $6.02 million, a P/E ratio of -0.23 and a beta of 1.55. The stock has a fifty day moving average price of $3.10 and a two-hundred day moving average price of $4.19.

Aeterna Zentaris Company Profile

Aeterna Zentaris Inc, a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests in Canada, Switzerland, Ireland, Denmark, Germany, the United States, and internationally. Its lead product is Macrilen (macimorelin), an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of patients with adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as endocrinology and oncology indications; AEZS-150, a delayed clearance parathyroid hormone fusion polypeptide that is in preclinical trial for the treatment of chronic hypoparathyroidism; and AEZS-130 that is in preclinical trial for the treatment of amyotrophic lateral sclerosis.